Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganitumab + Chemotherapy in Metastatic Ewing Sarcoma
NCT02306161Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2014
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of ganitumab in Ewing sarcoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Event-free Survival at 5 years. Started Dec 2014; status: active, not recruiting.
02
Drugs
ganitumab
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT02306161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02306161.